Xigen ^Company

Xigen is a privately-owned biopharmaceutical company founded in 2002 as a spin-off from the University Hospital of Lausanne (CHUV) that specializes in the development of peptides for use against inflammation. Xigen’s peptides have high stability and specificity. They are selectively delivered to their intracellular targets through proprietary carrier molecules. The company’s lead compound, XG-102, is a D-amino-acids peptide, highly selective, non-competitive, long-acting inhibitor of c-jun N-terminal kinase (JNK). Xigen’s second JNK inhibitor lead compound, namely XG-104, is a L/D-amino-acids peptide.

Xigen business model is based on the development and commercialisation of new therapeutic peptides through partnerships with pharma companies.
To achieve this goal, Xigen’s approach is to surround itself with dedicated and recognized professionals and international experts in drug development and inflammation in order to reach the demonstration of safety and clinical efficacy of drug candidates in the most expedite way.